ALK and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are crucial biological indicators for treating NSCLC patients with tyrosine kinase inhibitors (TKIs) [34, 35].